Versant Vantage II, L.P. — SEC insider filings
SEC reporting owner CIK 1832235. 20 insider filings on record with FilingPulse; latest filed 2026-10-28.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2021-06-23 to 2026-10-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 3 filings — 505,000 shares, $7,760,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 37 legs across 10 filings — 3,223,261 shares, $74,736,782 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 43.
- Largest priced transaction: sale of 350,000 shares @ $29.00 ($10,150,000) in LENZ Therapeutics, Inc., filed 2025-06-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | 10% owner | 10 | 1 leg · 180,000 sh · $3,060,000 | 34 legs · 1,885,262 sh · $66,603,139 | 5 |
| Century Therapeutics, Inc. (IPSC) | 10% owner | 4 | 1 leg · 100,000 sh · $2,000,000 | 1 leg · 550,000 sh · $7,166,610 | 7 |
| Turnstone Biologics Corp. (TSBX) | 10% owner | 2 | 4 legs · 225,000 sh · $2,700,000 | — | 27 |
| Tempest Therapeutics, Inc. (TPST) | 10% owner | 2 | — | 2 legs · 787,999 sh · $967,033 | — |
| Lycia Therapeutics, Inc. (LYCA) | 10% owner | 2 | — | — | 4 |
Insider filings — Versant Vantage II, L.P.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-28 | 4 | Lycia Therapeutics, Inc. (LYCA) jointly with Versant Ventures VII GP, L.P., Versant Venture Capital VII, L.P., Versant Ventures VII GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC | Conversion (C): 5,631,425 · Conversion (C): 1,393,882 · Conversion (C): 25,390,410 (derivative) · Conversion (C): 6,284,597 (derivative) | EDGAR |
| 2026-10-22 | 3 | Lycia Therapeutics, Inc. (LYCA) jointly with Versant Ventures VII GP, L.P., Versant Venture Capital VII, L.P., Versant Ventures VII GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC | Holdings only — no transactions reported | EDGAR |
| 2025-10-02 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 49,701 @ $45.35 · Sale (S): 34,405 @ $45.35 · Sale (S): 83,066 @ $46.41 · Sale (S): 57,502 @ $46.41 · Sale (S): 177 @ $47.01 · Sale (S): 123 @ $47.01 | EDGAR |
| 2025-09-22 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 49,479 @ $41.59 · Sale (S): 24,370 @ $41.59 · Sale (S): 40,907 @ $43.00 · Sale (S): 20,148 @ $43.00 · Sale (S): 268 @ $43.30 · Sale (S): 132 @ $43.30 | EDGAR |
| 2025-08-26 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 20,493 @ $40.03 · Sale (S): 10,076 @ $40.03 · Sale (S): 5,668 @ $40.59 · Sale (S): 2,809 @ $40.59 · Sale (S): 50,270 @ $39.53 · Sale (S): 24,760 @ $39.53 · +6 more | EDGAR |
| 2025-08-19 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 145,051 @ $39.50 · Sale (S): 69,949 @ $39.50 · Sale (S): 30,628 @ $38.56 · Sale (S): 15,085 @ $38.56 | EDGAR |
| 2025-08-12 | 4 | Turnstone Biologics Corp. (TSBX) jointly with Versant Ventures V, LLC, Versant Venture Capital V, L.P., Versant Ophthalmic Affiliates I, L.P., Versant Affiliates Fund V, L.P., Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Capital V (Canada), LP, Versant Vantage II GP-GP, LLC, Versant Vantage II GP, L.P. | Code (U): 2,726,322 · Code (U): 207,486 · Code (U): 90,888 · Code (U): 82,006 · Code (U): 274,990 | EDGAR |
| 2025-07-14 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 191,376 @ $34 | EDGAR |
| 2025-07-01 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 200,000 @ $30.46 | EDGAR |
| 2025-06-20 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 100,000 @ $29.95 · Sale (S): 100,877 @ $30.35 · Sale (S): 133,924 @ $30.25 | EDGAR |
| 2025-06-12 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 350,000 @ $29 | EDGAR |
| 2024-08-12 | 4 | Tempest Therapeutics, Inc. (TPST) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures IV, LLC, Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P. | Sale (S): 400,000 @ $1.35 · Sale (S): 387,999 @ $1.10 | EDGAR |
| 2024-03-25 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Other (J): 598,203 | EDGAR |
| 2023-07-27 | 4 | Turnstone Biologics Corp. (TSBX) jointly with Versant Ventures V, LLC, Versant Venture Capital V, L.P., Versant Ophthalmic Affiliates I, L.P., Versant Affiliates Fund V, L.P., Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Capital V (Canada), LP, Versant Vantage II GP-GP, LLC, Versant Vantage II GP, L.P. | Conversion (C): 2,528,864 · Conversion (C): 192,458 · Conversion (C): 84,313 · Conversion (C): 76,067 · Conversion (C): 274,990 · Purchase (P): 197,458 @ $12 · +20 more | EDGAR |
| 2022-08-11 | 4 | Century Therapeutics, Inc. (IPSC) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC | Sale (S): 550,000 @ $13.03 · Other (J): 364,800 @ $0 | EDGAR |
| 2022-05-03 | 4 | Tempest Therapeutics, Inc. (TPST) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures IV, LLC, Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P. | Holdings only — no transactions reported | EDGAR |
| 2022-02-02 | 4 | Century Therapeutics, Inc. (IPSC) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC | Other (J): 178,996 @ $0 | EDGAR |
| 2021-12-28 | 4 | Century Therapeutics, Inc. (IPSC) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC | Other (J): 371,004 @ $0 | EDGAR |
| 2021-07-01 | 4 | Graphite Bio, Inc. (GRPH) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC | Conversion (C): 12,343,727 · Conversion (C): 1,527,719 · Purchase (P): 180,000 @ $17 · Conversion (C): 30,019,945 (derivative) · Conversion (C): 3,715,415 (derivative) | EDGAR |
| 2021-06-23 | 4 | Century Therapeutics, Inc. (IPSC) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC | Conversion (C): 9,936,011 · Conversion (C): 614,095 · Purchase (P): 100,000 @ $20 · Conversion (C): 25,000,000 (derivative) @ $0 · Conversion (C): 1,545,125 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-06-15 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1832235 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs